The Sandoz Division is a global leader in generic pharmaceuticals and biosimilars, and sells products in more than 100 countries. The division has three global franchises: Retail Generics, Biopharmaceuticals and Anti-Infectives.
Sandoz net sales were USD 9.6 billion in 2021, decreasing by 2%1 (cc) from the previous year, as volume growth in our Biopharmaceuticals and contract manufacturing businesses was offset by the effects of price competition and continued headwinds for our Retail Generics business in the US. We continued to see an impact from COVID-19, particularly in the Retail Generics and Anti-Infectives businesses. However, the effects have been more moderate in recent months and the Sandoz business is continuing to normalize.
Sandoz sales in the Retail Generics business declined 4% (cc) to USD 7.1 billion, impacted primarily by continued sales volume decline in the US for oral solids as a result of partnership terminations.
Sales in the Biopharmaceuticals franchise grew 7% (cc) to USD 2.1 billion, driven by continued growth outside the US. Sandoz develops, manufactures and markets protein- and other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies.
In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for use by the Retail Generics franchise and for sale to third-party customers. Total franchise sales were USD 1.1 billion, a decrease of 5% (cc) from the prior year.
In 2021, Novartis announced that it will commence a strategic review of the Sandoz Division. The review will explore all options, ranging from retaining the business to separation, to determine how to best maximize value for our shareholders.